spacer
home > ebr > spring 2019 > opportunities and challenges in cancer innovations
PUBLICATIONS
European Biopharmaceutical Review

Opportunities and Challenges in Cancer Innovations

Progress is being made in the long-standing battle to effectively treat and control cancer. The National Cancer Institute projects that nearly five million more US citizens are expected to survive cancer in 2026 than in 2016 (1). Therapeutic tools like nextgeneration sequencing and advances in immunotherapy are just two ways that fundamental scientific breakthroughs and innovative thinking are moving the potential for cancer treatment forward.

One of the most revolutionary breakthroughs in this new era is cell and gene therapy. At its most basic definition, gene therapy (also called human gene transfer) is the therapeutic delivery of nucleic acid into a patientís cells as a drug to treat disease. According to The Journal of Gene Medicine, somewhere around 2,600 gene therapy clinical trials have been undertaken in 38 countries around the world as of November 2017 (2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Ger Brophy is Executive Vice President of Biopharma Production at Avantor. In his current role, he is responsible for developing and implementing the companyís biopharma production and supporting the current and future needs of customers. Prior to joining Avantor, Ger held a variety of R&D, strategy, advanced systems, and business development positions in the healthcare space with GE Healthcare Life Sciences, GE Healthcare Medical Diagnostics, and Amersham for nearly 30 years. He earned a BSc in biotechnology as well as a PhD in molecular biology from Dublin City University, Ireland.
spacer
Dr Ger Brophy
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo maintains its dual-terminal operations seamlessly

Completing the gradual transition process to Istanbul Airport, one of the largest airports of the world, the global air cargo brand Turkish Cargo maintains its dual-terminal operations with full capacity on 7/24 basis without any sales restriction.
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developerís mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement